Stock performance snapshot and recent context

Natera (NTRA) has drawn fresh investor attention after its share price closed at US$186.36, with the stock down 5.4% over the past day and 10.6% over the past month.

Over the past 3 months, Natera has fallen 11.8%, while the year-to-date performance shows a decline of 18.6%. Even so, its 1-year total return stands at 21.6%, and the 3-year total return is about 2.5x.

Natera’s recent share price weakness, including a 1-month share price return of down 10.6% and a year-to-date decline of 18.6%, contrasts with a 1-year total shareholder return of 21.6% and a very large 3-year total shareholder return. This suggests longer term momentum while near term enthusiasm has eased.

If you are reassessing growth stories in healthcare, it can be useful to compare Natera with other specialised opportunities using a focused screener for 28 healthcare AI stocks

With Natera’s shares pulling back despite strong multi year total returns and revenue growth of 14.8%, the stock now trades at a roughly 39% discount to one intrinsic estimate. This raises the question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 28.1% Undervalued

Against Natera’s last close at $186.36, the most followed valuation narrative points to a fair value of about $259.11, implying a sizeable gap that hinges on ambitious growth and profitability assumptions.

Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.

Curious what kind of revenue curve and margin lift would need to play out to support that fair value, and how long profitability improvements are projected to take.

The narrative uses a 7.08% discount rate and links the valuation to faster revenue growth than the broader US market, a shift from current losses toward positive earnings, and a higher future earnings multiple than many mature biotechs. These elements are combined into an implied fair value of $259.11 that treats Natera as a high growth diagnostic platform with meaningful operating leverage over time.

Result: Fair Value of $259.11 (UNDERVALUED)

However, you still need to weigh real risks, including potential setbacks in clinical trials or reimbursement decisions, as well as the impact of high ongoing R&D and SG&A spending on profitability.

Another way to look at Natera’s valuation

While the analyst narrative and fair value estimate lean on growth forecasts and discounted cash flows, current trading levels also tie back to a simple revenue multiple. Natera trades on a P/S of 10.7x, compared with a fair ratio of 7.6x, a peer average of 12.8x and a US Biotechs industry average of 10.6x. That mix of “expensive” versus the fair ratio yet cheaper than peers leaves a messy picture, so investors need to decide which anchor they want to rely on when sizing position risk.

Next Steps

With sentiment on Natera clearly mixed, now is a good time to review the data yourself and weigh the trade off between concerns and potential upside. To frame that assessment with a concise summary of both sides, review the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop your research at a single stock when you can quickly scan other opportunities that might better match your goals, time frame, and risk comfort.

• Target long term compounders by comparing quality companies trading below intrinsic estimates through the 51 high quality undervalued stocks.
• Prioritise resilience by reviewing companies with strong finances and low leverage using the solid balance sheet and fundamentals stocks screener (45 results).
• Get ahead of the crowd by spotting less followed opportunities via the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.